SOPHiA GENETICS (NASDAQ:SOPH) Announces Quarterly Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) announced its earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08), FiscalAI reports. SOPHiA GENETICS had a negative net margin of 41.13% and a negative return on equity of 37.75%. The business had revenue of $21.71 million for the quarter, compared to analysts’ expectations of $21.20 million.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• SOPHiA re-accelerated commercial momentum with Q4 revenue of $21.7M (+22% YoY), full-year 2025 revenue of $77.3M (+19%), 124 new customers signed in 2025, and guidance of $92–$94M (20–22% growth) for 2026.
• The platform and data moat are expanding—SOPHiA processed nearly 1 petabyte of genomic data in 2025, analyzed >391,000 patients, and rolled out a new SOPHiA DDM generation (adopted by ~1/3 of customers) that delivers 10x capacity per run and faster whole-genome analyses, helping adjusted gross margin rise to 74.2%.
• Biopharma momentum is building with a renewed global deal with AstraZeneca and a new global agreement with a top-5 pharma, but the company cautioned these partnerships are long-cycle and will contribute modestly near-term while offering upside in later 2026–2027.
• Implementation and product ramps improved—SOPHiA implemented a record 102 new customers in 2025, signed 70 sites for MSK‑ACCESS (about half live), and reported strong U.S. volume growth (analysis volumes +45% in Q4), though revenue is expected to be back‑half weighted in 2026 as new logos ramp.
• Liquidity and profitability path show progress but remain watchpoints—cash was $70.3M at YE2025 (plus ATM proceeds raised in Q1 2026 and a $25M credit expansion), adjusted EBITDA loss narrowed guidance to $29–$32M for 2026 with an expected crossover to positive adjusted EBITDA in H2 2027.

SOPHiA GENETICS Trading Down 11.3%

Shares of SOPH stock opened at $4.10 on Wednesday. The company has a market capitalization of $277.08 million, a PE ratio of -8.91 and a beta of 1.13. SOPHiA GENETICS has a 52-week low of $2.58 and a 52-week high of $5.70. The business’s fifty day moving average is $4.92 and its 200 day moving average is $4.43. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.62 and a current ratio of 2.80.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SOPH shares. Guggenheim upped their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.00.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC lifted its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Archon Capital Management LLC lifted its position in SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Federated Hermes Inc. grew its stake in SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after buying an additional 31,000 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of SOPHiA GENETICS by 169.5% in the 4th quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock worth $388,000 after buying an additional 52,200 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.